Gossamer Bio (GOSS) AI Stock Analysis

• Market Cap: $101.88M
• Dividend Yield: N/A
• Average Volume (3M): 23.41M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: -58.17%
• EPS Growth: -116.24%
• Country: US
• Employees: 144
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 231,456,250
• 10 Day Avg. Volume: 12,836,054
• 30 Day Avg. Volume: 23,414,483
• PEG Ratio: -0.02
• Price to Book (P/B): -5.77
• Price to Sales (P/S): 14.62
• P/FCF Ratio: -4.13
• Enterprise Value/Market Cap: 2.61
• Enterprise Value/Revenue: 5.50
• Enterprise Value/Gross Profit: 5.52
• Enterprise Value/Ebitda: -1.66
• 1Y Price Target: $3.69
• Price Target Upside: 757.14% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 8
• EPS Forecast (FY): -0.51
• Revenue Forecast (FY): $26.05M

• Rating: 40 Underperform
• Price Target: $0.43 ▲(0.70% Upside)
• Action: Downgraded Date: 03/17/26
• Date: Action: Downgraded 03/17/26

The score is driven primarily by very weak financial performance (widening losses, sharply higher cash burn, and negative equity) and bearish technical momentum (price far below key moving averages with negative MACD). Valuation provides limited support due to negative earnings, and the recent Phase 3 update adds uncertainty after missing the primary endpoint in the overall population.

Positive Factors

Subgroup efficacy signal

A pronounced and clinically meaningful 20m placebo-adjusted 6MWD improvement in prespecified intermediate/high-risk patients indicates seralutinib has differentiated activity in a defined population. This can support a narrower regulatory strategy, targeted labeling, and stronger commercial positioning within harder-to-treat PAH segments, preserving long-term value even if broader population benefit is uncertain.

Global collaboration (Chiesi)

A global partnership with Chiesi provides development expertise, regulatory support, and potential commercialization capacity outside the company. Structurally this reduces single-company execution risk, supplies non-dilutive milestone and royalty economics, and enhances strategic optionality for global market access if clinical signals translate to approval.

Ability to realize collaboration revenue

A recent quarter with $13.8M of revenue, above consensus, shows the company can capture material collaboration or milestone receipts. Recurring ability to realize non-product revenue from partners provides a predictable funding mechanism to support development programs and extend runway while the company remains pre-commercial.

Negative Factors

Large and widening losses

Sustained, large net losses materially weaken financial flexibility and increase reliance on external financing. Over time this elevates dilution and refinancing risk, constrains R&D investment choices, and reduces the company's ability to self-fund late-stage trials or commercialization, pressuring strategic options and partner negotiations.

Accelerated cash burn

A step-change in cash burn to roughly -$171M in 2025 sharply shortens runway and forces dependence on markets or partners for funding. This heightens the probability of dilutive financings or constrained program execution, and could delay or downscale trials if capital access tightens, harming long-term development plans.

Phase 3 miss & program uncertainty

Missing the prespecified primary endpoint in the overall Phase 3 population creates regulatory and commercial uncertainty and forces a strategic reassessment. Pausing enrollment raises timeline and execution risk, may reduce partner confidence, and makes approval in a crowded PAH add-on market less certain absent a clear regulatory path for subgroups.

Gossamer Bio Business Overview & Revenue Model

Company Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

How the Company Makes Money

Gossamer Bio has historically not been a product-revenue-generating company and has primarily funded operations through financing activities and collaboration economics rather than ongoing sales of approved drugs. As a clinical-stage biopharma, its potential revenue model centers on: (1) collaboration and partnering income—upfront payments, research funding, and potential development, regulatory, and commercial milestone payments from larger pharmaceutical partners tied to licensed programs; and (2) potential royalties on net sales if partnered products reach the market. The company has entered significant partnerships in the past (including a major collaboration with a large pharmaceutical company for a pulmonary hypertension program), which can provide non-recurring payments and future contingent economics if clinical and commercialization milestones are achieved. If the company later commercializes a drug itself, its revenue would come from product sales; however, specific, current, recurring product-sales revenue details are null because the company has not consistently generated meaningful commercial revenue from marketed products. Other sources of cash are typically equity offerings and, less commonly, debt, but these are financing sources rather than operating revenue.

Gossamer Bio Financial Statement Overview

Summary

Financials are very weak: large and worsening losses (2025 net loss about -$170M), sharply higher cash burn (2025 operating/free cash flow about -$171M vs. roughly -$3.5M in 2024), and a deteriorated balance sheet with equity turning negative in 2025 (-$123M) alongside meaningful debt (~$202M). Revenue has also been inconsistent (2025 ~$48M vs. 2024 ~$115M).

Income Statement

The company remains deeply unprofitable, with large operating losses in most years (e.g., EBIT of -$171M in 2025 vs. -$60M in 2024) and net losses that continue to be substantial (net income of -$170M in 2025). Revenue has been volatile: 2024 showed meaningful revenue ($115M) but 2025 revenue fell sharply to ~$48M despite a positive growth rate figure, highlighting inconsistency. Overall, weak profitability and unstable revenue visibility outweigh the occasional revenue contribution.

Balance Sheet

Leverage is a key concern given persistent losses and a debt load around ~$202M (2024–2025). The capital position weakened materially, with stockholders’ equity turning negative in 2025 (-$123M) from positive equity in 2024 (~$29M), which reduces financial flexibility and increases refinancing/dilution risk. Total assets also declined from ~$315M (2024) to ~$172M (2025), suggesting a shrinking balance sheet and potentially reduced liquidity cushion.

Cash Flow

Cash burn accelerated significantly in 2025, with operating cash flow at about -$171M and free cash flow also about -$171M, a sharp deterioration from 2024 when operating and free cash flow were near -$3.5M. The business has consistently generated negative free cash flow across the period, indicating ongoing reliance on external funding. While free cash flow has sometimes tracked net loss closely in prior years, the 2025 step-up in burn increases near-term funding risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	48.47M	114.70M	0.00	0.00	0.00
Gross Profit	47.47M	114.70M	0.00	0.00	0.00
EBITDA	-170.73M	-39.97M	-161.92M	-211.07M	-209.40M
Net Income	-170.37M	-56.53M	-179.82M	-229.38M	-234.00M
Balance Sheet
Total Assets	172.25M	315.29M	311.92M	272.45M	343.66M
Cash, Cash Equivalents and Short-Term Investments	136.93M	294.52M	296.43M	255.68M	325.22M
Total Debt	201.97M	202.88M	212.46M	225.74M	185.24M
Total Liabilities	295.01M	285.80M	249.15M	260.37M	222.19M
Stockholders Equity	-122.76M	29.49M	62.77M	12.08M	121.46M
Cash Flow
Free Cash Flow	-171.34M	-3.47M	-159.16M	-187.51M	-190.51M
Operating Cash Flow	-171.27M	-3.47M	-159.16M	-187.03M	-188.89M
Investing Cash Flow	156.36M	29.02M	-110.97M	-1.03M	-117.43M
Financing Cash Flow	6.42M	-11.49M	190.15M	117.09M	3.33M

Gossamer Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOSS, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.63, below the 50-day MA of 1.74, and below the 200-day MA of 2.21, indicating a bearish trend. The MACD of -0.40 indicates Negative momentum. The RSI at 23.46 is Positive, neither overbought nor oversold. The STOCH value of 15.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GOSS.

Gossamer Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MBX	54 Neutral	$1.36B	-13.24	-29.28%	―	―	-44.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTMX	47 Neutral	$748.82M	―	-19.77%	―	-10.26%	144.62%
SVRA	46 Neutral	$1.03B	-10.40	-84.01%	―	―	-22.39%
GOSS	40 Underperform	$101.88M	-4.16	242.63%	―	-58.17%	-116.24%

Gossamer Bio Corporate Events

Gossamer Bio Reveals Mixed Phase 3 Seralutinib Results

On February 23, 2026, Gossamer Bio reported topline Phase 3 PROSERA data showing that seralutinib did not meet the prespecified statistical threshold on its primary endpoint of six‑minute walk distance at Week 24 in the overall pulmonary arterial hypertension population, despite a nominally significant 13.3‑meter placebo‑adjusted gain. All four key secondary endpoints numerically favored seralutinib, including meaningful reductions in NT‑proBNP and trends toward better clinical improvement and risk score reduction, while safety was generally acceptable with more cough and higher liver enzyme elevations than placebo.

The trial revealed a notably stronger treatment effect in prespecified intermediate‑ and high‑risk patients, who achieved a 20‑meter placebo‑adjusted improvement in walk distance and robust biomarker and risk-score benefits, as well as a 37‑meter gain in connective tissue disease–associated PAH, suggesting differentiated value in these harder‑to‑treat segments. Operationally, Gossamer plans to pause enrollment in its SERANATA study to reassess development strategy and regional placebo effects, and will meet with U.S. regulators to determine whether these subgroup and secondary endpoint signals can support a viable path forward for seralutinib in a crowded PAH add‑on market.

The most recent analyst rating on (GOSS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Gossamer Bio stock, see the GOSS Stock Forecast page.